SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024. Presentation Details: Title:     Pha ...

BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Conference Call March 26, 2024 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Jay Short - Chairman, Chief Executive Officer and Co-Founder Richard Waldron - Chief Financial Officer Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Dev Prasad - Jefferies Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Reni Benjamin - Citizens JMP Securities Operator Greetings and welcome ...

Financial Performance - The company reported net losses of $123.5 million and $106.5 million for the years ended December 31, 2023 and 2022, respectively, with an accumulated deficit of $416.3 million as of December 31, 2023[407]. - The company reported a net loss of $123.5 million for the year ended December 31, 2023, compared to a net loss of $106.5 million in 2022, indicating an increase in losses of approximately 15.5%[429][430]. - The net loss for 2023 was $123.5 million, compared to a net loss of $106.5 million in 2022, resulting in a net loss per share of $2.58[456]. - Total operating expenses for 2023 were $129.7 million, a 19.9% increase from $108.1 million in 2022, driven primarily by research and development expenses of $103.7 million[456]. - Total stockholders' equity decreased from $180.3 million in 2022 to $70.7 million in 2023, a decline of 60.8%[453]. Research and Development - Research and development expenses increased to $103.7 million in 2023 from $79.3 million in 2022, primarily driven by advancements in clinical-stage ADC programs and other pre-clinical programs[419]. - The increase in research and development expenses includes a $11.2 million rise for Phase 2 clinical-stage ADC programs and a $7.4 million increase for the CTLA4 immuno-oncology program[420]. - Research and development expenses accounted for approximately 80% of total operating expenses in 2023, underscoring the company's focus on product development[456]. - The company is advancing multiple clinical development programs, including mecbotamab vedotin, ozuriftamab vedotin, evalstotug, and BA3182, which will require substantial additional capital[407]. - The company anticipates that its expenses and capital requirements will increase substantially as it advances its clinical development efforts[407]. Cash and Liquidity - As of December 31, 2023, cash and cash equivalents totaled approximately $111.5 million, expected to fund operations for at least twelve months[410]. - Cash used in operating activities was $104.0 million in 2023, up from $90.4 million in 2022, reflecting a year-over-year increase of 15.8%[429][430]. - Cash and cash equivalents at the end of 2023 were $111.5 million, down from $215.5 million at the end of 2022, indicating a significant decrease in liquidity[461]. - The company plans to fund its ongoing losses through public or private equity or debt financings, with a potential gross sales proceeds of up to $100 million from an Open Market Sale Agreement[466]. - The company expects to face challenges in raising additional capital due to market volatility and other economic factors[428]. Collaborations and Revenue - The company has entered into collaborations and licensing agreements that may provide future milestone and royalty payments, but did not recognize any revenue from these agreements in 2023 or 2022[412]. - The company has not recognized any revenue from the BeiGene collaboration for the years ended December 31, 2023, and 2022[536]. - The collaboration agreement with Bristol-Myers Squibb did not impact the Company's financial results for the years ended December 31, 2023, or 2022[537]. Assets and Liabilities - As of December 31, 2023, the company reported total assets of $119.7 million, a decrease of 46.9% from $225.7 million in 2022[452]. - Total current assets decreased from $220.4 million in 2022 to $116.4 million in 2023, a decline of 47%[452]. - Total liabilities increased from $45.4 million in 2022 to $49.0 million in 2023, an increase of 5.8%[453]. - The company's accumulated deficit increased to $416.3 million in 2023, up from $292.8 million in 2022, reflecting ongoing operational losses[453]. Stock and Equity - The total number of common stock options outstanding increased from 2,736,918 in 2022 to 6,273,507 in 2023[495]. - The total number of restricted stock units increased from 510,039 in 2022 to 99,104 in 2023[495]. - The total number of common shares authorized for issuance under the 2020 Equity Incentive Plan increased to 9,196,970 in 2023 from 7,658,509 in 2022, an increase of 20.1%[520]. - The total unrecognized stock-based compensation cost for unvested common stock options was $15.6 million, expected to be recognized over approximately 2.8 years[527]. - The Company issued 165,550 shares under the Employee Stock Purchase Plan (ESPP) in 2023, compared to 147,564 shares in 2022[531]. Tax and Deferred Assets - The Company had federal net operating loss carryforwards of approximately $119.2 million, which can be carried forward indefinitely, subject to an 80% limitation against taxable income[554]. - The Company established a valuation allowance of approximately $85.6 million as of December 31, 2023, to offset deferred tax assets, which increased by approximately $28.9 million during 2023[553]. - The Company had gross unrecognized tax benefits of approximately $3.6 million as of December 31, 2023, none of which would affect the effective tax rate due to the valuation allowance[559]. Operational Insights - The impact of the COVID-19 pandemic on the company's operations remains uncertain and will depend on future developments[411]. - The Company views its operations as a single operating segment, streamlining performance assessment[470]. - The Company has not entered into any off-balance sheet arrangements as defined by SEC rules and regulations[440]. - The Company has not experienced any losses in its cash accounts and believes it is not exposed to significant credit risk[473].

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024 – CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024 – CAB-AXL (BA3011) P ...

Financial Data and Key Metrics Changes - Cash and cash equivalents as of September 30, 2023, were $141.3 million, down from $215.5 million as of December 31, 2022, with expectations to fund operations into the second half of 2025 [20] - Research and development expenses for Q3 2023 were $28.4 million, an increase from $19.8 million in Q3 2022, primarily due to clinical product development expenses [20] - General and administrative expenses were $6.6 million for Q3 2023, slightly up from $6.3 million in Q3 2022 [21] - Net loss for Q3 2023 was $33.3 million, compared to a net loss of $25.8 million in Q3 2022 [21] Business Line Data and Key Metrics Changes - BA3011 Phase II study in non-small cell lung cancer showed an objective response rate of 27.8% among patients previously treated with PD-1 therapy [7] - In patients with EGFR wild-type, non-squamous lung cancer, 33.3% had a partial response to BA3011 monotherapy [7] - BA3021, a CAB-ROR2-ADC, completed enrollment of approximately 20 patients in both lung cancer and melanoma studies, with early responses observed [11] Market Data and Key Metrics Changes - AXL expression in lung cancer is associated with poor prognosis, with patients in the study having a median of three prior lines of therapy [8] - The company is exploring the potential clinical benefits of BA3011 in AXL TmPS negative patients, which could broaden market opportunities [8] Company Strategy and Development Direction - The company aims to form strategic collaborations with major pharmaceutical partners to accelerate the development of selected assets [6] - Focus remains on delivering innovative therapies to cancer patients with significant unmet medical needs, particularly through the CAB platform [10] Management's Comments on Operating Environment and Future Outlook - Management received verbal FDA feedback supportive of a registrational path for BA3011 in lung cancer, with formal written feedback expected soon [26] - The company believes that the CAB platform demonstrates compelling clinical efficacy and safety across multiple therapeutic targets [23] Other Important Information - Dr. Bin Zhang joined as Senior Vice President, Head of Clinical Development and Operations, bringing over 20 years of experience in oncology drug development [18] - An abstract on BA3011 was accepted for presentation at the IASLC conference in December [19] Q&A Session Summary Question: Feedback on registrational path for BA3011 - Management received clear and actionable items from the FDA regarding the registrational path and expects to communicate more details in December [26] Question: Details on IASLC conference presentation - A standard poster presentation will include data sets, including spider plots and swimmers plots, with updates on combination therapy and more frequent dosing data [28][29] Question: Competition in non-small cell lung cancer - Management noted that responses at low AXL expression levels hint at broader market opportunities, with ongoing evaluations of AXL negative patients [33][35] Question: Data sharing for non-small cell lung cancer - Management confirmed that data on non-small cell lung cancer will be shared at an upcoming meeting, with a focus on prioritizing AXL lung for that indication [37] Question: Enrollment status for bispecific candidate BA3182 - Enrollment is progressing well, with the study actively dosing and showing positive early results [43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman & Chief Medical Officer Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Tony Butler - E.F. Hutton Reni Benjamin - JMP Securities Operator Greetings, and welcome to the B ...

jay and car UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation ...

BioAtla, Inc. (NASDAQ:BCAB) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman and CEO Richard Waldron - CFO Philippe Martin - Chief CDO Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Reni Benjamin - JMP Securities Arthur He - H.C. Wainwright Operator Greetings. And welcome to the BioAtla First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A b ...